Blasenerhaltende multimodale Therapiekonzepte

Zusammenfassung

In deutschen und internationalen Leitlinien wird die organerhaltende Behandlung des muskelinvasiven Harnblasenkarzinoms für geeignete Patient*innen als onkologisch gleichwertige therapeutische Alternative zur radikalen Zystektomie deklariert. Aktuelle, hochrangig publizierte Daten beschreiben für die multimodale Therapie im Vergleich zur Operation einen Vorteil im Gesamtüberleben.

Publikationsverlauf

Artikel online veröffentlicht:
18. Februar 2025

• Literatur

• 1 Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. Atlas der Krebsinzidenz und -mortalität in Deutschland (GEKIDAtlas). http://www.gekid.de
• 2 Moll F. Anfänge der modernen Urochirurgie im 19. Jahrhundert. In: Schultheiss D, Rathert P, Jonas U. Streiflichter aus der Geschichte der Urologie Berlin. Heidelberg, Deutschland: Springer Verlag; 2000
• 3 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 2.0, 2020. AWMF-Registrierungsnummer 032/038OL. https://www.leitlinienprogramm-onkologie.de/leitlinien/harnblasenkarzinom/
• 4 Choudhury A, Porta N, Hall E. et al. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. The lancet oncology 2021; 22: 246-255
• 5 Ott OJ, Gaipl US, Lamrani A. et al. The Emerging Evidence Supporting Integration of Deep Regional Hyperthermia With Chemoradiation in Bladder Cancer. Semin Radiat Oncol 2023; 33: 82-90
• 6 Huddart RA, Hall E, Hussain SA. et al. Randomized noninferiority trial of reduced highdose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Int J Radiat Oncol Biol Phys 2013; 87: 261-269
• 7 Krause FS, Walter B, Ott OJ. et al. 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. Anticancer Res 2011; 31: 985-990
• 8 James ND, Hussain SA, Hall E. et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. The New England journal of medicine 2012; 366: 1477-1488
• 9 Hall E, Hussain SA, Porta N. et al. Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial. European urology 2022; 82: 273-279
• 10 Ott OJ, Rodel C, Weiss C. et al. Radiochemotherapy for bladder cancer. Clin Oncol (R Coll Radiol) 2009; 21: 557-565
• 11 van der Zee J, Gonzalez Gonzalez D, van Rhoon GC. et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000; 355: 1119-1125
• 12 Wittlinger M, Rodel CM, Weiss C. et al. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia. Radiother Oncol 2009; 93: 358-363
• 13 Merten R, Ott O, Haderlein M. et al. Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2). Oncologist 2019; 24: e1341-e1350
• 14 Huddart RA, Hall E, Lewis R. et al. Life and death of spare (selective bladder preservation against radical excision): reflections on why the spare trial closed. BJU international 2010; 106: 753-755
• 15 Kotwal S, Choudhury A, Johnston C. et al. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys 2008; 70: 456-463
• 16 Munro NP, Sundaram SK, Weston PM. et al. A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK. Int J Radiat Oncol Biol Phys 2010; 77: 119-124
• 17 Booth CM, Siemens DR, Li G. et al. Curative therapy for bladder cancer in routine clinical practice: a population-based outcomes study. Clin Oncol (R Coll Radiol) 2014; 26: 506-514
• 18 Cahn DB, Handorf EA, Ghiraldi EM. et al. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer. Cancer 2017; 123: 4337-4345
• 19 Bekelman JE, Handorf EA, Guzzo T. et al. Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: examining confounding and misclassification biasin cancer observational comparative effectiveness research. Value Health 2013; 16: 610-618
• 20 Arcangeli G, Strigari L, Arcangeli S. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials. Crit Rev Oncol Hematol 2015; 95: 387-396
• 21 Zlotta AR, Ballas LK, Niemierko A. et al. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multiinstitutional propensity score matched and weighted analysis. The lancet oncology 2023; 24: 669-681